Reply to Satapathy et al.'s comment on "Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022" [0.03%]
关于Satapathy等人对“比利时2014-2022年HIV护理连续体的双重横断面和纵向视角，以区分自然流行病演化和真正进展”的评论的回复
Dominique Van Beckhoven,Ben Serrien,Rémy Demeester et al.
Dominique Van Beckhoven et al.
Comment on "Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022" [0.03%]
关于“从双重横断面和纵向视角解析HIV护理连续体以区分自然流行病演变和真实进步，2014-2022年比利时”的评论
Prajnasini Satapathy,Rachana Mehta,Ranjana Sah
Prajnasini Satapathy
Assessing cancer-related mortality risk among people with HIV in Vietnam: A nationwide population study [0.03%]
越南HIV感染者癌症相关死亡风险的全国人口研究
Ngoan Tran Le,Ngan Dieu-Thi Ta,Thao Thi-Thu Vu et al.
Ngoan Tran Le et al.
Background: Despite the growing burden of comorbidities, including cancer, among people with HIV, there is a lack of empirical evidence on cancer-related mortality in this vulnerable population in Vietnam. ...
Authors' Reply to Letter to the Editor Regarding 'Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study' [0.03%]
关于“恩曲他滨/ tenofovir alafenamide方案治疗HIV-1感染的有效性，安全性和患者报告结局的最终24个月结果：德国TAFNES队列研究”的信件答复
Christoph Stephan,Boris Albuquerque,Sandra Schreiber
Christoph Stephan
User-reported outcomes of long-acting injectable PrEP with Cabotegravir: Real-world experience from Milan [0.03%]
卡博特韦长效注射型暴露前预防在米兰的真实世界应用体验：基于患者报告的结果
Angelo Roberto Raccagni,Flavia Passini,Riccardo Lolatto et al.
Angelo Roberto Raccagni et al.
Introduction: Oral HIV pre-exposure prophylaxis (PrEP) is highly effective, but adherence and persistence are often limited by side effects, pill fatigue and stigma. Long-acting injectable cabotegravir (CAB-LA) offers a d...
HIV PrEP use and unmet need among gay, bisexual and other men who have sex with men in London: An analysis of community cross-sectional surveys in England 2019-2022 [0.03%]
伦敦男男性行为者中HIV暴露前预防药物的使用情况及未被满足的需求：一项英格兰2019-2022年社区横断面调查分析
Flavien Coukan,Dana Ogaz,John Saunders et al.
Flavien Coukan et al.
Objectives: In England, HIV pre-exposure prophylaxis (PrEP) was routinely commissioned at sexual health services from 2020. We compared PrEP use and unmet need among gay, bisexual and other men who have sex with men (GBMS...
Bernard Surial,Jasmini Alagaratnam
Bernard Surial
Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program [0.03%]
HIV感染者的性別心血管疾病差異及相關因素：All Of Us计划的证据分析
Hao Zhang,Huiyi Xia,Fanghui Shi et al.
Hao Zhang et al.
Background: People living with HIV (PLWH) face a higher risk of cardiovascular disease (CVD), with significant sex differences in outcomes. However, it is unclear whether these differences are driven by distinct risk fact...
Identification of GSR and CBR1 as biomarkers in HIV-associated emphysema through transcriptomic analysis [0.03%]
通过转录组分析鉴定GSR和CBR1作为HIV相关肺气肿的生物标志物
Jian-Cheng Zhu,Wei-Ping Hu,Jing Zhang
Jian-Cheng Zhu
Background: With the widespread use of antiretroviral therapy (ART), life expectancy among people living with human immunodeficiency virus (HIV) infection has significantly increased. However, studies on HIV-associated em...
Informal PrEP use in Greece: The long, hard road to formal programmatic implementation [0.03%]
希腊的非正式使用PrEP情况：漫长而艰难的正式项目实施之路
Konstantinos Protopapas,Charalampos D Moschopoulos,Nikolaos Kalesis et al.
Konstantinos Protopapas et al.
Objectives: Pre-exposure prophylaxis (PrEP) with antiretroviral drugs (ARVs) is a highly effective HIV prevention strategy. Although the European Medicines Agency approved oral PrEP in 2016 and the World Health Organizati...